alantolactone has been researched along with Cancer of Pancreas in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, X; He, R; Li, X; Pan, S; Qin, R; Shi, X; Wang, M; Zhao, C; Zhao, Y; Zhou, M | 1 |
| Chen, M; Dai, X; Huang, X; Kang, Y; Li, C; Liang, G; Lin, S; Xiang, Y; Yang, L; Zhao, C; Zheng, H | 1 |
2 other study(ies) available for alantolactone and Cancer of Pancreas
| Article | Year |
|---|---|
Alantolactone induces apoptosis and improves chemosensitivity of pancreatic cancer cells by impairment of autophagy-lysosome pathway via targeting TFEB.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Lactones; Lysosomes; Oxaliplatin; Pancreatic Neoplasms; Phagosomes; Sesquiterpenes, Eudesmane; Signal Transduction | 2018 |
Alantolactone sensitizes human pancreatic cancer cells to EGFR inhibitors through the inhibition of STAT3 signaling.
Topics: Animals; Apoptosis; Cell Cycle; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lactones; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Protein Kinase Inhibitors; Sesquiterpenes, Eudesmane; Signal Transduction; STAT3 Transcription Factor; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |